Dexmedetomidine and hydromorphone: A novel pain management strategy for the oncology ward setting during anti‐GD2 immunotherapy for high‐risk neuroblastoma in children

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|1|29-34

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.1, 2015-01, pp. : 29-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Value of surgical resection in children with high‐risk neuroblastoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1529-1535

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of high-risk neuroblastoma in children: recent clinic trial results

By Greengard Emily   Hill-Kayser Christine   Bagatell Rochelle  

Clinical Investigation, Vol. 3, Iss. 11, 2013-11 ,pp. : 1071-1081

Future Science

Access to resources Recommend Favorite

The role of chest computed tomography (CT) as a surveillance tool in children with high‐risk neuroblastoma

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 976-981

John Wiley & Sons Inc

Access to resources Recommend Favorite

Allergic reactions and antiasparaginase antibodies in children with high‐risk acute lymphoblastic leukemia: A children's oncology group report

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4205-4211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Osteochondroma in long‐term survivors of high‐risk neuroblastoma

By  

CANCER, Vol. 121, Iss. 12, 2015-06 ,pp. : 2090-2096

John Wiley & Sons Inc

Access to resources Recommend Favorite